{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:55:03Z","timestamp":1769756103122,"version":"3.49.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cjca.2022.02.022","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T11:10:32Z","timestamp":1645873832000},"page":"S79-S88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2965-1504","authenticated-orcid":false,"given":"Guillaume","family":"Marquis-Gravel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Robert-Halabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin R.","family":"Bainey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamir R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2022.02.022_bib1","first-page":"214","article-title":"2018 Canadian Cardiovascular Society (CCS)\/Canadian Association of Interventional Cardiology (CAIC) focused update of the guidelines for the use of antiplatelet therapy","volume":"34","author":"Mehta","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2022.02.022_bib3","article-title":"A\u00a0critical comparison of canadian and international guidelines recommendations for antiplatelet therapy in coronary artery disease","author":"Marquis-Gravel","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib4","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/ATVBAHA.107.141911","article-title":"Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis","volume":"27","author":"Mackman","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2022.02.022_bib6","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMra1011670","article-title":"The hemostatic system as a modulator of atherosclerosis","volume":"364","author":"Borissoff","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/nm1102-1227","article-title":"Platelets in atherothrombosis","volume":"8","author":"Ruggeri","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib8","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","article-title":"Aspirin, sulfinpyrazone, or both in unstable angina","volume":"313","author":"Cairns","year":"1985","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib9","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib10","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT\u2013OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2022.02.022_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2022.02.022_bib12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Th\u00e9roux","year":"1988","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease","volume":"384","author":"Yusuf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib15","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","article-title":"CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.02.022_bib16","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease","volume":"384","author":"Jones","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib17","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A\u00a0clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina","volume":"309","author":"Lewis","year":"1983","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib19","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib20","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary interventiona randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2022.02.022_bib21","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib22","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib23","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ahj.2016.08.008","article-title":"A\u00a0critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease","volume":"181","author":"Welsh","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2022.02.022_bib25","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.amjcard.2020.12.018","article-title":"Overview of aspirin and platelet biology","volume":"144","author":"Santos-Gallego","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(88)92833-4","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2","volume":"332","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2022.02.022_bib27","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJM198806303182603","article-title":"Aspirin and dipyridamole in the prevention of re-stenosis after percutaneous transluminal coronary angioplasty","volume":"318","author":"Schwartz","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCINTERVENTIONS.111.964197","article-title":"A\u00a0randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention","volume":"5","author":"Welsh","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2022.02.022_bib31","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib32","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib33","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2022.02.022_bib34","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2022.02.022_bib35","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.jacc.2020.03.011","article-title":"Ticagrelor with or without aspirin after complex PCI","volume":"75","author":"Dangas","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib36","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","article-title":"Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"75","author":"Angiolillo","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib37","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention. The SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2022.02.022_bib38","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.02.022_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Baigent","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2022.02.022_bib40","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes","volume":"108","author":"Peters Ron","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.02.022_bib41","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/eurheartj\/ehn417","article-title":"Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study","volume":"30","author":"Jolly","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2022.02.022_bib42","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamacardio.2020.0116","article-title":"Rationale and design of the aspirin dosing\u2014A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) Trial","volume":"5","author":"Marquis-Gravel","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib43","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jacc.2016.11.050","article-title":"Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus","volume":"69","author":"Bhatt","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib44","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.116.023164","article-title":"Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus","volume":"134","author":"Capodanno","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.02.022_bib45","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCINTERVENTIONS.110.960187","article-title":"Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease","volume":"4","author":"Capodanno","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2022.02.022_bib49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1527-3466.1993.tb00275.x","article-title":"Clopidogrel, a novel antiplatelet and antithrombotic agent","volume":"11","author":"Herbert","year":"1993","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.cjca.2022.02.022_bib50","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke","volume":"333","author":"Gent","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2022.02.022_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.CIR.82.1.17","article-title":"Studio della Ticlopidina nell\u2019Angina Instabile Group. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial","volume":"82","author":"Balsano","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.02.022_bib52","first-page":"909","article-title":"Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative","volume":"13","author":"Gill","year":"1997","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib53","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ahj.2005.01.044","article-title":"Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study","volume":"150","author":"Lewis","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2022.02.022_bib54","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000051362.96946.15","article-title":"Early and late effects of clopidogrel in patients with acute coronary syndromes","volume":"107","author":"Yusuf","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2022.02.022_bib55","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2022.02.022_bib56","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2022.02.022_bib57","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2022.02.022_bib58","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2022.02.022_bib59","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","article-title":"Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of nonresponders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease","volume":"27","author":"Jernberg","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2022.02.022_bib60","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1517\/14656566.9.16.2893","article-title":"Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development","volume":"9","author":"Angiolillo","year":"2008","journal-title":"Exp Opin Pharmacother"},{"key":"10.1016\/j.cjca.2022.02.022_bib61","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1124\/dmd.107.020248","article-title":"The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2","volume":"36","author":"Williams","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cjca.2022.02.022_bib62","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib63","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2125.2010.03669.x","article-title":"Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers","volume":"70","author":"Butler","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2022.02.022_bib64","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/heartjnl-2015-308963","article-title":"Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention","volume":"102","author":"Velders","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2022.02.022_bib65","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2022.02.022_bib66","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"57","author":"Held","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib67","first-page":"1377","article-title":"Outcomes among clopidogrel, prasugrel, and ticagrelor in ST-elevation myocardial infarction patients who underwent primary percutaneous coronary intervention from the TOTAL trial","volume":"35","author":"Welsh","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib68","first-page":"1283","article-title":"\u201cTicagrelor or Prasugrel, Doctor?\u201d The basis for decision in clinical practice","volume":"35","author":"Marquis-Gravel","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib69","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.cjco.2020.11.021","article-title":"Implications of the antiplatelet therapy gap left with discontinuation of prasugrel in Canada","volume":"3","author":"Lordkipanidz\u00e9","year":"2020","journal-title":"CJC Open"},{"key":"10.1016\/j.cjca.2022.02.022_bib70","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2022.02.022_bib71","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2022.02.022_bib72","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non\u2013ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib73","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib74","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2020.05.031","article-title":"Post-discharge bleeding and subsequent mortality after acute coronary syndrome treated with or without PCI","volume":"76","author":"Marquis-Gravel","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib75","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention","volume":"66","author":"Genereux","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib76","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.jacc.2019.08.997","article-title":"Efficacy and Safety of ticagrelor monotherapy in patients undergoing multivessel PCI","volume":"74","author":"Takahashi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib77","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamacardio.2019.3355","article-title":"Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial","volume":"4","author":"Tomaniak","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2022.02.022_bib78","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2022.02.022_bib79","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2022.02.022_bib80","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X22001490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X22001490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:49:56Z","timestamp":1760107796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X22001490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0828282X22001490"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2022.02.022","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2022.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}